SAN DIEGO - Cardiff Oncology, Inc. (NASDAQ:CRDF) announced Monday it will present updated data from its CRDF-004 Phase 2 clinical trial at the American Society of Clinical Oncology Annual Meeting, ...

In March 2026, Immutep discontinued its Phase III TACTI-004 trial in first-line non-small cell lung cancer after an interim futility analysis showed patients on eftilagimod alfa with KEYTRUDA and ...

Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trialRoot cause ...

Robbins LLP is Investigating Allegations that Immutep Limited Misled Investors Regarding the Viability and Efficacy of its Drug Candidate According to the complaint, during the class period, ...

For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen ...

Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the ...

Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark ...

MA’s ZEPHYR Phase 2 trial in schizophrenia Last patient visit completed for ML-004’s IRIS Phase 2 trial in autism spectrum disorderTopline results from both Phase 2 trials expected by mid-August 2026 ...

Cynata Therapeutics has secured firm commitments to raise $1.5 million through an institutional placement as it awaits Phase ...

Rare Pediatric Disease Designation may render Pasithea eligible to receive a Priority Review Voucher (PRV)MIAMI, April 20, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ...

Clinuvel Pharmaceuticals (ASX:CUV) is conducting a Phase III trial to expand the indications for Scenesse (afamelanotide), ...

Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the ...